Suven Pharmaceuticals Limited Share Price Bombay S.E.

Equities

SUVENPHAR

INE03QK01018

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:48 29/04/2024 pm IST 5-day change 1st Jan Change
644.4 INR -2.04% Intraday chart for Suven Pharmaceuticals Limited +1.07% -11.25%
Sales 2023 13.4B 161M Sales 2024 * 10.9B 131M Capitalization 168B 2.01B
Net income 2023 4.11B 49.3M Net income 2024 * 3.34B 40.06M EV / Sales 2023 8.97 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 15.4 x
P/E ratio 2023
29.2 x
P/E ratio 2024 *
50.2 x
Employees 1,193
Yield 2023 *
0.36%
Yield 2024 *
0.27%
Free-Float 37.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.04%
1 week+1.07%
Current month-4.75%
1 month-3.87%
3 months-5.80%
6 months+14.60%
Current year-11.25%
More quotes
1 week
626.90
Extreme 626.9
664.10
1 month
608.35
Extreme 608.35
687.15
Current year
586.10
Extreme 586.1
767.00
1 year
427.05
Extreme 427.05
767.00
3 years
375.00
Extreme 375
767.00
5 years
87.05
Extreme 87.05
767.00
10 years
87.05
Extreme 87.05
767.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 29/23/29
Director of Finance/CFO 30 01/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 29/23/29
Director/Board Member 48 09/11
Director/Board Member 62 09/11
More insiders
Date Price Change Volume
29/24/29 644.4 -2.04% 7 479
26/24/26 657.9 +2.02% 3,939
25/24/25 644.8 +1.27% 5,898
24/24/24 636.8 -1.10% 1,651
23/24/23 643.8 +0.98% 5,883

Delayed Quote Bombay S.E., April 29, 2024 at 03:30 pm IST

More quotes
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
659.7 INR
Average target price
685.5 INR
Spread / Average Target
+3.91%
Consensus